Memory Chip Market: Is the Decline an Opportunity?

The Russell 2000 also fell, extending the weakness in small and mid-cap stocks. According to Orlando Kim's explanation, this can be read as capital moving out of the Nasdaq and into the Dow.

Infrastructure stocks including Intel and semiconductor equipment stocks also declined, while security stocks and software names such as Oracle corrected as well, with weakness pronounced across the broader tech sector.

Orlando Kim argued that higher oil prices fuel dollar strength, which pushes down gold and bitcoin prices.

The yen-dollar exchange rate reached 158 yen, and as European economic concerns grew, preference for U.S. bonds intensified.

China's largest memory maker, CXMT, may release DDR5 server memory using a 4F-square cell structure by year-end, potentially ahead of Samsung and SK hynix. Major memory companies including Micron saw their shares plunge on the report.

Market concern grew over the possibility of this technological lead, and the output is reportedly likely to be supplied first to China's own data centers. Analysts say this could affect long-term DRAM price volatility more than Micron's HBM business.

Elon Musk assessed that once China masters a production method, it scales faster than the rest of the world combined. This is linked to China's production capacity, already proven in lithium batteries and solar.

Experts pointed out that implementing HBM architecture or stacking RAM on logic demands very high technical difficulty, and that China's production capacity and cutting-edge technology are separate issues.

Barclays analysis projects Micron's DRAM supply will remain constrained through 2018, and both spot and contract prices for DDR4 and DDR5 continue to rise.

New supply contracts are shifting toward structures that reflect market volatility rather than fixed prices, and these supply constraints are expected to support growth in the AI memory market.

On news that CXMT (ChangXin Memory Technologies) will launch new products based on a 4F square cell architecture, Micron's shares fell over 4%, stoking market unease.

However, analysts say the change in Nvidia's revenue share reflects Micron's diversifying customer base and rapid growth among other customer groups, so despite short-term anxiety, the long-term growth trend remains valid.

Goldman Sachs recommends increasing exposure to U.S. and Asian equities and maintains an optimistic view in its three-month and 12-month outlooks.

The S&P 500's 12-month forward P/E fell from 22x at the start of the year to 19.1x, easing valuation pressure, and there is strong expectation that valuations could expand if interest rates are cut.

Surging bond yields have limited gains, but analysts argue that corporate earnings growth will continue to support the market.

As upward pressure on non-food and energy prices has eased, Goldman raised its 12-month bond recommendation from neutral to overweight starting in September.

Goldman Sachs changed its 12-month bond rating from neutral to overweight starting in September, explaining that limited upward pressure on non-food and energy prices is expected to ease tightening policy.

This strategy could allow the 10-year Treasury to serve as a hedge rather than a headwind.

FactSet expects 10% earnings growth for the banking sector, but Orlando Kim stressed that the macroeconomic views bank executives present this quarter matter more than the earnings figures.

In an economy struggling with rising oil prices and interest rate hikes, whether executives comment on consumer sentiment and lending activity is drawing attention.

Strong corporate earnings are tending to lower P/E ratios, and there is hope that strength in AI data center construction will drive earnings growth.

Headline CPI is forecast to rise 3.6% year over year, higher than the previous month's 3.4%. Core personal consumption expenditures (PCE) prices are expected to slow to 0.2% from 0.3% the previous month.

The market rally is being led by the stocks of a few large AI-related companies whose growth is strong enough to outweigh rising capital costs.

As the equal-weight index trailed the S&P 500 by roughly 6%, average stocks absorbed larger losses from the surge in long-term rates, showing a concentration effect.

There is strong evidence that the current high yields stem from capital demand for growth.

The real spread, the federal funds rate minus CPI inflation, stands at 3.88%, lower than in the past.

Expectations of strong market-wide earnings could improve the outlook for the market, according to analysts.

Meta expects capital expenditure of $145 billion this year and projects an increase of $240 billion to $260 billion going forward, continuing to expand its AI investment.

The current share price is about 5% below its 52-week high, and with a P/E of 17x, valuation pressure is not heavy, highlighting its investment appeal.

Since shares are down 60% from their May peak, it sees a buy-the-dip opportunity.

The company operates the only space-based broadband network that connects directly to smartphones, and expectations are building around possible changes in T-Mobile's satellite partner and winning Japanese government projects.

With the share price down 60% from its May peak, it is viewed as a buy-on-weakness zone.

Bank of America upgraded Salesforce two notches to buy and raised its target price sharply from $160 to $285.

Bank of America analyzed that Salesforce will achieve a leap forward by integrating AI into its business, strengthening business logic and workflows.

Evercore ISI rated Robinhood an expert in new product development and monetization, presenting a buy rating and a $130 target price. This implies 19% upside from Friday's close.

Robinhood is growing its deposit base by more than 20% and expanding its customer base with one-stop financial services. It has achieved $100 million in revenue across 13 products, and new product launches are analyzed as a key factor that will positively affect future share price growth.

JPMorgan upgraded Biogen from neutral to overweight and set a $300 target price, implying 33% upside.

According to JPMorgan, Biogen plans to report clinical results for key pipeline drugs such as Leqembi and lecanemab-related candidates by 2027, and it is also paying attention to the market potential of the rare kidney disease treatment Fabhalta.